Bachem Holding AG - Company Profile
Powered by 
All the sales intelligence you need on Bachem Holding AG in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Bachem Holding AG fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Bachem Holding AG.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Bachem Holding AG (Bachem) is a company specialising in the development and manufacture of peptides and oligonucleotides. The company offers products that include peptides for research, clinical development, and commercial application, oligonucleotides, custom synthesis, catalog peptides, peptide APIs, amino acid derivatives, cosmetic peptides, peptides for medical devices, and oligonucleotide APIs. Its products are used for the treatment of various conditions such as cardiovascular diseases, metabolic disorders, cancer and infectious diseases, among others. The company provides API manufacturing, process development, regulatory support, custom synthesis, project management and other analytical services. The company's products are utilised by customers in various industries for medical and scientific applications. Bachem operates internationally with locations in Europe, the US, and Asia, targeting global markets. Bachem is headquartered in Bubendorf, Switzerland.
Headquarters
Switzerland
Address
Hauptstrasse 144, Bubendorf, 4416
Website
www.bachem.com
Telephone
41 58 5952020
No of Employees
2,511
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BANB (SWF)
Revenue (2024)
$836.9M
14.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
23.7%
(2024 vs 2023)
Market Cap*
$6.9B
Net Profit Margin (2024)
XYZ
7.8%
(2024 vs 2023)
* As of and is in US$
Bachem Holding AG premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Peptides: | Project Management | BACHEM |
| Peptide NCE Development (New Chemical Entities) | Quality and Regulatory | |
| Custom Synthesis | Analytical Capabilities | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In November, the company entered into a partnership with TIRmed Pharma to develop and manufacture TIR-01, the active ingredient in next-generation atopic dermatitis therapy. |
| 2025 | Plans/Strategy | In October, the company announced plans to expand peptide and oligonucleotide manufacturing capacity in Vista, California, the US. |
| 2023 | Contracts/Agreements | In March, Bachem Group signed a new framework agreement to provide large volumes of peptides. |
Competitor Comparison
| Key Parameters | Bachem Holding AG | Lonza Group Ltd | Avantor Inc | Celltrion Inc | Siegfried Holding AG |
|---|---|---|---|---|---|
| Headquarters | Switzerland | Switzerland | United States of America | South Korea | Switzerland |
| City | Bubendorf | Basel | Radnor | Incheon | Zofingen |
| State/Province | - | Basel-Stadt | Pennsylvania | Gangwon | Aargau |
| No. of Employees | 2,511 | 16,866 | 13,500 | 1,074 | 3,891 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Kuno Sommer | Chairman | Executive Board | 2012 | 70 |
| Anne-Kathrin Stoller | Chief Commercial Officer; Chief Executive Officer | Senior Management | 2026 | - |
| Alain Schaffter | Chief Financial Officer | Senior Management | 2020 | 49 |
| Hans Van Hees | Chief Operating Officer | Senior Management | 2025 | 57 |
| Gunther Loidl | Chief Technology Officer | Senior Management | 2015 | 56 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer